NCT00504530已完成1 期
A Randomised, Double-blind, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Acceptability of r-hLIF for Improving Embryo Implantation Following in Vitro Fertilisation (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 50
- 主要终点
- Improvement of embryo implantation and Safety
研究概览
简要总结
This study was designed to obtain pilot clinical evidence of the efficacy, safety and acceptability of r-hLIF administered during the luteal phase after IVF/intra-cytoplasmic sperm injection (ICSI) and ET for improving embryo implantation in infertile women with a history of at least three implantation failures following ART. Based on LIF expression patterns and experimental data from animal research a role of LIF in embryo implantation is anticipated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 21 Years 至 36 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pre-menopausal woman aged 21 to 36 years, inclusive, at time of consent
- •Infertile woman who justified IVF-ET or ICSI-ET treatment and who wished to conceive
- •A history of at least three ART cycles resulting in a transfer of at least two apparently healthy embryos and no evidence of implantation menstruation and/or beta hCG < 10 IU/L at the end of the cycle)
- •Had regular ovulatory spontaneous menstrual cycles lasting 25 to 35 days
- •Had FSH assessment (early follicular day 2 to 5) within the past six months < 12 IU/L
- •No other diagnosed cause of previous ART failure other than recurrent implantation failure
- •A body mass index (BMI) of ³ 20 and £ 30 kg/m2, calculated according to the following formula: BMI (kg/m2) = Body Weight (kg) / Height * Height (m2)
- •The presence of both ovaries
- •A uterine cavity without abnormalities which, in the investigator's opinion, could impair embryo implantation or pregnancy outcome, as assessed by ultrasound (US) examination performed within six months prior to beginning GnRH-agonist therapy
- •Normal cervical cytology within three years prior to beginning GnRH- agonist therapy.
- •At least one wash-out cycle (defined as ³ 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment, prior to beginning GnRH-agonist therapy
- •Male partner semen analysis within the six months prior to starting GnRH agonist therapy
- •Had a negative pregnancy test (urinary) within seven days of commencing GnRH-agonist therapy.
- •Willingness and ability to comply with the protocol for the duration of the study
- •Written informed consent given prior to any study related procedure not part of the patient's normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
排除标准
- •Known to be positive for Human Immunodeficiency Virus
- •Known to be positive for Hepatitis B or C Virus
- •Known allergy to E. coli derived pharmaceutical product
- •Any clinically significant systemic disease (e.g. insulin-dependant diabetes mellitus, epilepsy, severe migraine, intermittent porphyria, hepatic, renal or cardiovascular disease, severe corticosteroid-dependent asthma) or any significant allergic disease (excluding rhinitis, hay fever or sinusitis of ENT origin)
- •Presence of an uncontrolled clinically significant medical condition (including infection) as determined by the investigator
- •Persistent tachycardia defined as heart rate > 90 bpm confirmed by ECG
- •Any medical condition, which in the judgement of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug. In case of doubt, the patient in question was to be discussed with Serono's Study Director
- •More than one previous failed ART cycle, where "failed" is defined as cancellation of administration of hCG due to a poor response to gonadotrophin stimulation (defined as retrieval of three oocytes or less)
- •Any history of difficulties in ET procedure (i.e. requiring general anaesthetic e.g. due to position of cervix)
- •Hyperprolactinaemia, defined as prolactin levels of ³ 1000 mIU/L and/or the patient remained anovulatory despite appropriate dopamine agonist treatment
- •Abnormal undiagnosed gynaecological bleeding
- •Any contraindication to being pregnant and/or carrying pregnancy to term
- •Presence of any medical condition for which the use of gonadotrophin preparations or progesterone was contra-indicated
- •Known allergy or hypersensitivity to gonadotrophin preparations
- •Known intolerance or allergy to paracetamol (acetaminophen)
- •Active substance abuse
- •Previous entry into this study or simultaneous participation in another clinical drug trial
结局指标
主要结局
Improvement of embryo implantation and Safety
时间窗: Various
次要结局
- Secondary endpoints were implantation rate, proportion of patients with biochemical pregnancy and the number of live births.(various)
研究者
相似试验
已完成
2 期
Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative IleusIleusNCT05056935Newsoara Biopharma Co., Ltd.131
已完成
2 期
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel ResectionIleusPost-Operative AdhesionsNCT02836470Palisade Bio112
已完成
2 期
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's SyndromePrimary Sjögren's SyndromeNCT02775916Novartis Pharmaceuticals30
已完成
1 期
TD-6450 MAD Study in HCV Infected SubjectsHCVHepatitis CNCT02116543Theravance Biopharma47
已完成
2 期
To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With ConjunctivochalasisConjunctivochalasisNCT02810119Ocuwize LTD13